123 related articles for article (PubMed ID: 2958486)
21. Urokinase-type plasminogen activator regulates cranial neural crest cell migration in vitro.
Agrawal M; Brauer PR
Dev Dyn; 1996 Nov; 207(3):281-90. PubMed ID: 8922527
[TBL] [Abstract][Full Text] [Related]
22. Factor XI enhances fibrin generation and inhibits fibrinolysis in a coagulation model initiated by surface-coated tissue factor.
von dem Borne PA; Cox LM; Bouma BN
Blood Coagul Fibrinolysis; 2006 Jun; 17(4):251-7. PubMed ID: 16651866
[TBL] [Abstract][Full Text] [Related]
23. The dissolution of human cross-linked plasma fibrin clots by the equimolar human plasmin-derived light (B) chain-streptokinase complex. The acceleration of clot lysis by pretreatment of fibrin clots with the light (B) chain.
Summaria L; Boreisha IG; Arzadon L; Robbins KC
Thromb Res; 1977 Sep; 11(3):377-89. PubMed ID: 144332
[No Abstract] [Full Text] [Related]
24. Influence of homocysteine on fibrin network lysis.
Lauricella AM; Quintana I; Castañon M; Sassetti B; Kordich L
Blood Coagul Fibrinolysis; 2006 Apr; 17(3):181-6. PubMed ID: 16575255
[TBL] [Abstract][Full Text] [Related]
25. Fibrin-specificity of a plasminogen activator affects the efficiency of fibrinolysis and responsiveness to ultrasound: comparison of nine plasminogen activators in vitro.
Sakharov DV; Barrertt-Bergshoeff M; Hekkenberg RT; Rijken DC
Thromb Haemost; 1999 Apr; 81(4):605-12. PubMed ID: 10235448
[TBL] [Abstract][Full Text] [Related]
26. Plasminogen activator/plasmin system suppresses cell-cell adhesion of oral squamous cell carcinoma cells via proteolysis of E-cadherin.
Hayashido Y; Hamana T; Yoshioka Y; Kitano H; Koizumi K; Okamoto T
Int J Oncol; 2005 Sep; 27(3):693-8. PubMed ID: 16077918
[TBL] [Abstract][Full Text] [Related]
27. Effects of low molecular weight heparins on fibrin polymerization and clot sensitivity to t-PA-induced lysis.
Parise P; Morini M; Agnelli G; Ascani A; Nenci GG
Blood Coagul Fibrinolysis; 1993 Oct; 4(5):721-7. PubMed ID: 8292721
[TBL] [Abstract][Full Text] [Related]
28. Simplified recombinant plasmin: production and functional comparison of a novel thrombolytic molecule with plasma-derived plasmin.
Hunt JA; Petteway SR; Scuderi P; Novokhatny V
Thromb Haemost; 2008 Sep; 100(3):413-9. PubMed ID: 18766256
[TBL] [Abstract][Full Text] [Related]
29. [A method for determining plasmin by the rate of fibrin gel lysis].
Popova GIu; Eremeev NL; Aĭsina RB; Kazanskaia NF
Biull Eksp Biol Med; 1989 May; 107(5):561-4. PubMed ID: 2525408
[TBL] [Abstract][Full Text] [Related]
30. Studies on the specific fibrinolytic effect of human extrinsic (tissue-type) plasminogen activator in human blood and in various animal species in vitro.
Korninger C; Collen D
Thromb Haemost; 1981 Aug; 46(2):561-5. PubMed ID: 6795744
[TBL] [Abstract][Full Text] [Related]
31. [Intensification of the effect of exogenous plasminogen activators on lysis of fibrin blood clots due to a decrease in the level of alpha-2- antiplasmin by a plasmasorption method].
Ogloblina OG; Saburova OS; Semenova OA; Belova LA
Biokhimiia; 1994 Jan; 59(1):62-8. PubMed ID: 7509643
[TBL] [Abstract][Full Text] [Related]
32. Tissue plasminogen activator (tPA) inhibits plasmin degradation of fibrin. A mechanism that slows tPA-mediated fibrinolysis but does not require alpha 2-antiplasmin or leakage of intrinsic plasminogen.
Wu JH; Diamond SL
J Clin Invest; 1995 Jun; 95(6):2483-90. PubMed ID: 7769094
[TBL] [Abstract][Full Text] [Related]
33. The fibrinogenolytic activity of purified tryptase from human lung mast cells.
Schwartz LB; Bradford TR; Littman BH; Wintroub BU
J Immunol; 1985 Oct; 135(4):2762-7. PubMed ID: 3161948
[TBL] [Abstract][Full Text] [Related]
34. An experimental and theoretical study on the dissolution of mural fibrin clots by tissue-type plasminogen activator.
Wootton DM; Popel AS; Alevriadou BR
Biotechnol Bioeng; 2002 Feb; 77(4):405-19. PubMed ID: 11787013
[TBL] [Abstract][Full Text] [Related]
35. Transport phenomena and clot dissolving therapy: an experimental investigation of diffusion-controlled and permeation-enhanced fibrinolysis.
Wu JH; Siddiqui K; Diamond SL
Thromb Haemost; 1994 Jul; 72(1):105-12. PubMed ID: 7974357
[TBL] [Abstract][Full Text] [Related]
36. Regulation of gelatinase activity in mice with targeted inactivation of components of the plasminogen/plasmin system.
Lijnen HR; Silence J; Lemmens G; Frederix L; Collen D
Thromb Haemost; 1998 Jun; 79(6):1171-6. PubMed ID: 9657444
[TBL] [Abstract][Full Text] [Related]
37. In vitro fibrin clot formation and fibrinolysis using heterozygous plasma fibrinogen from gammaAsn319, Asp320 deletion dysfibrinogen, Otsu I.
Terasawa F; Kani S; Hongo M; Okumura N
Thromb Res; 2006; 118(5):651-61. PubMed ID: 16412498
[TBL] [Abstract][Full Text] [Related]
38. Plasmin in pericellular proteolysis and cellular invasion.
Kramer MD; Reinartz J; Brunner G; Schirrmacher V
Invasion Metastasis; 1994-1995; 14(1-6):210-22. PubMed ID: 7657514
[TBL] [Abstract][Full Text] [Related]
39. Mafenide (Sulfamylon) inhibits plasmin fibrinolytic activity.
Weisdorf DJ; Aldridge JH
Thromb Haemost; 1988 Jun; 59(3):440-4. PubMed ID: 2973151
[TBL] [Abstract][Full Text] [Related]
40. [Inhibition of esterase by L-lysine, the activator and fibrinolytic activity of the plasmin-streptokinase activator complex].
Aĭsina RB; Gaĭsarian ES; Snitko IaE; Varfolomeev SD
Bioorg Khim; 1994 Feb; 20(2):182-9. PubMed ID: 8155080
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
